Irreversible electroporation‑mediated shRNA knockdown of the HPV18 E6 gene suppresses cervical cancer growth in vitro and in vivo

Wang,Zhi‑Liang; Zhou,Wei; Xiong,Zheng‑Ai; Yu,Teng‑Hua; Wu,Li‑Mei; Li,Cheng‑Xiang; Yao,Cheng‑Guo; Wu,Yu‑Tong; Hua,Yuan‑Yuan

doi:10.3892/ol.2017.6405

Irreversible electroporation‑mediated shRNA knockdown of the HPV18 E6 gene suppresses cervical cancer growth in vitro and in vivo

Authors:
- Zhi‑Liang Wang
- Wei Zhou
- Zheng‑Ai Xiong
- Teng‑Hua Yu
- Li‑Mei Wu
- Cheng‑Xiang Li
- Cheng‑Guo Yao
- Yu‑Tong Wu
- Yuan‑Yuan Hua
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, P.R. China, Department of Obstetrics, Chongqing Health Center for Women and Children, Chongqing 400013, P.R. China, Department of Breast Surgery, Jiangxi Cancer Hospital, Nanchang 330029, P.R. China, State Key Laboratory of Power Transmission Equipment and System Security and New Technology, Chongqing University, Chongqing 400044, P.R. China
Published online on: June 16, 2017 https://doi.org/10.3892/ol.2017.6405
Pages: 1943-1949
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Irreversible electroporation (IRE) is a physical, non‑thermal cancer therapy, which leads to cell death via permanent membrane permeability. This differs from reversible electroporation (RE), which is used to transfer macromolecules into target cells via transient membrane permeability. Given the electrical impedance of the electric field, RE co‑exists outside the central zone of IRE ablation. In the present study, the feasibility of using IRE at a therapeutic dose to mediate short hairpin RNA (shRNA) knockdown of human papillomavirus (HPV)18 E6 in HeLa cervical cancer cells in vitro and in vivo was investigated. Experimental results indicated that the HeLa cells survived the combined treatment with IRE and shRNA plasmid transfection. Additionally, residual tumor tissue in a nude mouse model demonstrated green fluorescence. Subsequent studies showed that the combined treatment inhibited the growth of HeLa cells and tumors. Western blotting analysis showed marked changes in the growth‑associated proteins between the combined treatment group and the control. It was concluded that a therapeutic dose of IRE was able to mediate the transfection of HPV18 E6 shRNA into HeLa cervical cancer cells in vitro and in vivo. This combined treatment strategy has promising implications in cancer treatment for the ablation of tumors, and in eliminating microscopic residual tumor tissue.

View Figures

View References

1	Neumann E, Schaefer-Ridder M, Wang Y and Hofschneider PH: Gene transfer into mouse lyoma cells by electroporation in high electric fields. EMBO J. 1:841–845. 1982.PubMed/NCBI
2	Yarmush ML, Golberg A, Serša G, Kotnik T and Miklavčič D: Electroporation-based technologies for medicine: Principles, applications, and challenges. Annu Rev Biomed Eng. 16:295–320. 2014. View Article : Google Scholar : PubMed/NCBI
3	Golberg A and Yarmush ML: Nonthermal irreversible electroporation: Fundamentals, applications, and challenges. IEEE Trans Biomed Eng. 60:707–714. 2013. View Article : Google Scholar : PubMed/NCBI
4	Mir LM, Belehradek M, Domenge C, Orlowski S, Poddevin B, Belehradek J Jr, Schwaab G, Luboinski B and Paoletti C: Electrochemotherapy, a new antitumor treatment: First clinical trial. C R Acad Sci III. 313:613–618. 1991.(In French). PubMed/NCBI
5	Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, Munster PN, Sullivan DM, Ugen KE, Messina JL and Heller R: Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol. 26:5896–5903. 2008. View Article : Google Scholar : PubMed/NCBI
6	Granot Y and Rubinsky B: Mass transfer model for drug delivery in tissue cells with reversible electroporation. Int J Heat Mass Transf. 51:5610–5616. 2008. View Article : Google Scholar : PubMed/NCBI
7	Otten G, Schaefer M, Doe B, Liu H, Srivastava I, zur Megede J, O'Hagan D, Donnelly J, Widera G, Rabussay D, et al: Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine. 22:2489–2493. 2004. View Article : Google Scholar : PubMed/NCBI
8	Davalos RV, Mir IL and Rubinsky B: Tissue ablation with irreversible electroporation. Ann Biomed Eng. 33:223–231. 2005. View Article : Google Scholar : PubMed/NCBI
9	Pech M, Janitzky A, Wendler JJ, Strang C, Blaschke S, Dudeck O, Ricke J and Liehr UB: Irreversible electroporation of renal cell carcinoma: A first-in-man phase I clinical study. Cardiovasc Intervent Radiol. 34:132–138. 2011. View Article : Google Scholar : PubMed/NCBI
10	Cheung W, Kavnoudias H, Roberts S, Szkandera B, Kemp W and Thomson KR: Irreversible electroporation for unresectable hepatocellular carcinoma: Initial experience and review of safety and outcomes. Technol Cancer Res Treat. 12:233–241. 2013. View Article : Google Scholar : PubMed/NCBI
11	Martin RC II, McFarland K, Ellis S and Velanovich V: Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma. J Am Coll Surg. 215:361–369. 2012. View Article : Google Scholar : PubMed/NCBI
12	Martin RC II, McFarland K, Ellis S and Velanovich V: Irreversible electroporation in locally advanced pancreatic cancer: Potential improved overall survival. Ann Surg Oncol. 20 Suppl 3:S443–S449. 2013. View Article : Google Scholar : PubMed/NCBI
13	Neal RE II, Millar JL, Kavnoudias H, Royce P, Rosenfeldt F, Pham A, Smith R, Davalos RV and Thomson KR: In vivo characterization and numerical simulation of prostate properties for non-thermal irreversible electroporation ablation. Prostate. 74:458–468. 2014. View Article : Google Scholar : PubMed/NCBI
14	Golberg A, Bruinsma BG, Uygun BE and Yarmush ML: Tissue heterogeneity in structure and conductivity contribute to cell survival during irreversible electroporation ablation by ‘electric field sinks’. Sci Rep. 5:84852015. View Article : Google Scholar : PubMed/NCBI
15	Ellis TL, Garcia PA, Rossmeisl JH Jr, Henao-Guerrero N, Robertson J and Davalos RV: Nonthermal irreversible electroporation for intracranial surgical applications. Laboratory investigation. J Neurosurg. 114:681–688. 2011. View Article : Google Scholar : PubMed/NCBI
16	Guo Y, Zhang Y, Klein R, Nijm GM, Sahakian AV, Omary RA, Yang GY and Larson AC: Irreversible electroporation therapy in the liver: Longitudinal efficacy studies in a rat model of hepatocellular carcinoma. Cancer Res. 70:1555–1563. 2010. View Article : Google Scholar : PubMed/NCBI
17	Joyce TA, Wong J, Mittra A, Carpenter S, Haddad D, Carson J, Jayaraman S, Monette S, Solomon SB, Ezell P and Fong Y: Irreversible electroporation is a surgical ablation technique that enhances gene transfer. Surgery. 150:474–479. 2011. View Article : Google Scholar : PubMed/NCBI
18	Chen L, Wu YY, Liu P, Wang J, Wang G, Qin J, Zhou J and Zhu J: Down-regulation of HPV18 E6, E7, or VEGF expression attenuates malignant biological behavior of human cervical cancer cells. Med Oncol. 28 Suppl 1:S528–S539. 2011. View Article : Google Scholar : PubMed/NCBI
19	Zhou W, Xiong Z, Liu Y, Yao C and Li C: Low voltage irreversible electroporation induced apoptosis in HeLa cells. J Cancer Res Ther. 8:80–85. 2012. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Rosty C, Sheffer M, Tsafrir D, Stransky N, Tsafrir I, Peter M, de Crémoux P, de La Rochefordière A, Salmon R, Dorval T, et al: Identification of a proliferation gene cluster associated with HPV E6/E7 expression level and viral DNA load in invasive cervical carcinoma. Oncogene. 24:7094–7104. 2005. View Article : Google Scholar : PubMed/NCBI
22	Doorbar J: Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci (Lond). 110:525–541. 2006. View Article : Google Scholar : PubMed/NCBI
23	Breton M and Mir LM: Microsecond and nanosecond electric pulses in cancer treatments. Bioelectromagnetics. 33:106–123. 2012. View Article : Google Scholar : PubMed/NCBI
24	Jiang C, Davalos RV and Bischof JC: A review of basic to clinical studies of irreversible electroporation therapy. IEEE Trans Biomed Eng. 62:4–20. 2015. View Article : Google Scholar : PubMed/NCBI
25	Beveridge JR, Wall K, MacGregor SJ, Anderson JG and Rowan NJ: Pulsed electric field inactivation of spoilage microorganisms in alcoholic beverages and the influence of pulse profile. Proc IEEE. 92:pp. 1138–1143. 2004; View Article : Google Scholar
26	Joyce TA, Mittra A, Song TJ, Cavnar M, Jun K, Carson J, Gholami S, Haddad D, Gaujoux S, Monette S, et al: Irreversible electroporation facilitates gene transfer of a GM-CSF plasmid with a local and systemic response. Surgery. 154:496–503. 2013. View Article : Google Scholar : PubMed/NCBI
27	Rubinsky B, Onik G and Mikus P: Irreversible electroporation: A new ablation modality-clinical implications. Technol Cancer Res Treat. 6:37–48. 2007. View Article : Google Scholar : PubMed/NCBI